Randomized comparison of early and late vaccination with inactivated poliovirus vaccine after allogeneic BMT.
Forty-five adult HLA-matched sibling BMT recipients were randomized to receive inactivated poliovirus vaccine (IPV) at 6, 8 and 14 months (early group, n = 23) or at 18, 20 and 26 months after BMT (late group, n = 22). Ninety-five percent of the early group patients had protective antibody titres of > or = 4 to poliovirus type 1 (PV1), poliovirus type 2 (PV2) and poliovirus type 3 (PV3) by a microneutralization assay prior to the first vaccination, at 6 months after BMT. The corresponding proportion for the late group patients was only 67% at 18 months. The antibody responses 1 month after each of the three IPV doses were similar in the two vaccination groups, except that four-fold responses occurred more frequently after the first dose to PV2 and PV3 in the late group. All patients had a protective antibody titre to all poliovirus serotypes 1 and 22 months after the third vaccine dose, except one patient in the early group who lacked antibodies to PV3 at 22 months. Acute GVHD accelerated the decrease of poliovirus antibody titres prior to vaccination but had no influence on vaccination response. Chronic GVHD neither influenced the patient's ability to retain poliovirus antibodies prior to vaccination nor impaired responses to vaccinations. A vaccination schedule consisting of three IPV doses was equally immunogenic when started at 6 or 18 months after allogeneic BMT.
Parkkali
T
T
Department of Medicine, Helsinki University Central Hospital, Finland.
Stenvik
M
M
Ruutu
T
T
Hovi
T
T
Volin
L
L
Ruutu
P
P
D000328:Adult; D000914:Antibodies, Viral / Q000032:analysis; D016026:Bone Marrow Transplantation / Q000276:immunology*; D005260:Female; D006086:Graft vs Host Disease / Q000276:immunology; D006801:Humans; D007115:Immunization Schedule; D008297:Male; D008875:Middle Aged; D011051:Poliomyelitis / Q000276:immunology / Q000517:prevention & control; D011054:Poliovirus Vaccine, Inactivated / Q000008:administration & dosage* / Q000276:immunology; D011446:Prospective Studies; D019172:Transplantation Conditioning; D015164:Vaccines, Inactivated / Q000008:administration & dosage* / Q000276:immunology
D000914:Antibodies, Viral; D011054:Poliovirus Vaccine, Inactivated; D015164:Vaccines, Inactivated